|Day Low/High||29.10 / 30.11|
|52 Wk Low/High||23.15 / 34.50|
There are reasons to proceed with extreme caution in the current market, including the possibility that the U.S. won't have a divided government.
Supernus Pharmaceuticals and Strongbridge Biopharma both recently turned in better-than-expected quarterly results.
The early stages of the pandemic hurt sales at many biotech companies, but there are signs that revenue streams are picking back up.
American Airlines, Supernus Pharmaceuticals and TPI Composites should see their fortunes improve this year.
Sharp drops in Heron Therapeutics and Supernus Pharmaceuticals have presented opportunities to make lemonade out of lemons.
A look at Supernus Pharmaceuticals and TPI Composites provides a tutorial on reaping rewards from stocks the market suddenly hates.
Karyopharm Therapeutics and Pieris Pharmaceuticals are climbing this week on positive news, while Supernus Pharmaceuticals takes a hit.
Both stocks have seen some recent insider buying.
For investors interested in biotech, there's a lot to choose from, with options ranging from startups with potentially blockbuster new treatments to companies those that have been around the block a few times.
Exelixis Inc., ANI Pharmaceuticals and Supernus Pharmaceuticals should not need to raise more capital in the foreseeable future.
Markets off to a decent start to the trading day with all the major indices up a half hour into trading. Some of the names I have profiled in recent months are on the move early today. Let's take a look at a few of these: T2 Biosystems after posting...
One way or another I continue to believe that some sort of tax legislation will be signed before the end of the year.
Broad strength and good tone mark action.
Here's why to check out Dynavax Technologies as well Lexicon, Supernus and Acadia Pharmaceuticals.
Demographic trends that boosted big gains in prior years haven't gone away.
This is the time of the year when many moves are made for tax reasons.
The number of new 12-month highs has climbed to 240.
These small-caps are woefully undervalued after getting shellacked in October.
Thanks to everyone who contributed to the conversation on the Daily Diary today. It was quite a lively bunch. I wish the market could have held earlier highs, but at least it was a positive end to a volatile trading week and a downright brutal one f...
Given the biotech's growth prospects and pipeline assets, its shares seem greatly undervalued.
Buyers expect a dovish Fed and are still trying to put money to work.
Despite the unsettled market, there are still some interesting picks out there.
IPO Desktop President Francis Gaskins believes both Envivio and Supernus are a little risky for investors.